Preliminary observations on human trabecular meshwork cells in vitro

1980 ◽  
Vol 212 (3-4) ◽  
pp. 173-186 ◽  
Author(s):  
I. Grierson ◽  
E. Robins ◽  
R. C. Howes
2020 ◽  
Vol 10 (1) ◽  
pp. 78
Author(s):  
April Nettesheim ◽  
Myoung Sup Shim ◽  
Angela Dixon ◽  
Urmimala Raychaudhuri ◽  
Haiyan Gong ◽  
...  

Extracellular matrix (ECM) deposition in the trabecular meshwork (TM) is one of the hallmarks of glaucoma, a group of human diseases and leading cause of permanent blindness. The molecular mechanisms underlying ECM deposition in the glaucomatous TM are not known, but it is presumed to be a consequence of excessive synthesis of ECM components, decreased proteolytic degradation, or both. Targeting ECM deposition might represent a therapeutic approach to restore outflow facility in glaucoma. Previous work conducted in our laboratory identified the lysosomal enzyme cathepsin B (CTSB) to be expressed on the cellular surface and to be secreted into the culture media in trabecular meshwork (TM) cells. Here, we further investigated the role of CTSB on ECM remodeling and outflow physiology in vitro and in CSTBko mice. Our results indicate that CTSB localizes in the caveolae and participates in the pericellular degradation of ECM in TM cells. We also report here a novel role of CTSB in regulating the expression of PAI-1 and TGFβ/Smad signaling in TM cells vitro and in vivo in CTSBko mice. We propose enhancing CTSB activity as a novel therapeutic target to attenuate fibrosis and ECM deposition in the glaucomatous outflow pathway.


1993 ◽  
Vol 57 (5) ◽  
pp. 557-565 ◽  
Author(s):  
Jean E. Kawa ◽  
Eve J. Higginbotham ◽  
Isabel L. Chang ◽  
Beatrice Y.J.T. Yue

2013 ◽  
Vol 251 (7) ◽  
pp. 1741-1746 ◽  
Author(s):  
Ashish Sharma ◽  
Alammaprabhu Jayaprakash Patil ◽  
Saffar Mansoor ◽  
Maria F. Estrago-Franco ◽  
Vincent Raymond ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (9) ◽  
pp. e0221942 ◽  
Author(s):  
Stefania Vernazza ◽  
Sara Tirendi ◽  
Sonia Scarfì ◽  
Mario Passalacqua ◽  
Francesco Oddone ◽  
...  

2017 ◽  
Vol 41 ◽  
pp. 21-29 ◽  
Author(s):  
Meryem Bouchemi ◽  
Christophe Roubeix ◽  
Karima Kessal ◽  
Luisa Riancho ◽  
Anne-Laure Raveu ◽  
...  

Nanomedicine ◽  
2017 ◽  
Vol 12 (16) ◽  
pp. 1911-1926 ◽  
Author(s):  
Vibhuti Agrahari ◽  
Guorong Li ◽  
Vivek Agrahari ◽  
Iris Navarro ◽  
Kristin Perkumas ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Megumi Watanabe ◽  
Yosuke Ida ◽  
Hiroshi Ohguro ◽  
Chiaki Ota ◽  
Fumihito Hikage

AbstractTo establish appropriate ex vivo models for a glaucomatous trabecular meshwork (TM), two-dimensional (2D) and three-dimensional (3D) cultures of human trabecular meshwork cells (HTM) were prepared in the presence of 250 nM dexamethasone (DEX) or 5 ng/mL TGFβ2, and characterized by the following analyses; transendothelial electrical resistance (TEER) measurements, FITC dextran permeability, scanning electron microscopy and the expression of the extracellular matrix (ECM) including collagen (COL)1, 4 and 6, and fibronectin (FN), α-smooth muscle actin (α-SMA), tissue inhibitor of metalloproteinase (TIMP)1–4, and matrix metalloproteinase (MMP)2, 9 and 14. DEX and TGFβ2 both caused a significant increase or decrease in the TEER values and FITC dextran permeability. During the 3D spheroid culture, DEX or TGFβ2 induced a mild and significant down-sizing and an increase in stiffness, respectively. TGFβ2 induced a significant up-regulation of COL1 and 4, FN, α-SMA, and MMP 2 and 14 (2D) or COL1 and 6, and TIMP2 and 3 (3D), and DEX induced a significant up-regulation of FN (3D) and TIMP4 (2D and 3D). The findings presented herein indicate that DEX or TGFβ2 resulted in mild and severe down-sized and stiff 3D HTM spheroids, respectively, thus making them viable in vitro HTM models for steroid-induced and primary open angle glaucoma.


Sign in / Sign up

Export Citation Format

Share Document